Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06971185 · ClinicalTrials.gov registry record
A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept
A clinical trial of Myelodysplastic Syndromes (MDS), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 430
- Enrollment target
- 1
- Study location
NCT06971185 is a study of Myelodysplastic Syndromes (MDS) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 430 participants, above the 147-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (193% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06971185, a study of Myelodysplastic Syndromes (MDS), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 430 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
Conditions Studied
Interventions
- DRUG Luspatercept
- DRUG Erythropoiesis-stimulating agent (ESA)
Study Locations (1)
New Jersey
- Bristol Myers Squibb - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2025-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06971185
The ClinicalTrials.gov registry entry for NCT06971185 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 147-participant average among 10 other Myelodysplastic Syndromes (MDS) trials with a reported enrollment target (193% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelodysplastic Syndromes (MDS) appearing as the primary indexed condition, and to 2 interventions - of which Luspatercept is the first listed.
NCT06971185 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06971185 about?
NCT06971185 is a clinical study titled "A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept". The purpose of this study is to understand the treatment patterns and clinical outcomes of myelodysplastic syndromes patients treated with luspatercept or erythropoiesis-stimulating agents
What is the current status of trial NCT06971185?
This trial is currently active not recruiting. The enrollment target is 430 participants. The study started on 2024-11-22. Estimated completion is 2025-08-01.
What conditions does trial NCT06971185 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes (MDS).
What interventions are being tested in trial NCT06971185?
The interventions under investigation include: Luspatercept (DRUG), Erythropoiesis-stimulating agent (ESA) (DRUG).
Who is sponsoring clinical trial NCT06971185?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06971185 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
RECRUITING · Phase 3
-
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RECRUITING · Early Phase 1
-
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
RECRUITING · NA
-
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.